Skip to main content
. Author manuscript; available in PMC: 2015 Jun 5.
Published in final edited form as: Am J Obstet Gynecol. 2015 Jan 9;212(6):717–724. doi: 10.1016/j.ajog.2015.01.012

TABLE 5.

Cases of uterine sarcoma and outcomes after morcellation

Author Year
published		 Study
years		 n Nonmorcellated
cases, n		 Morcellated cases, n Outcome
measure		 Level of
evidence
Perri et al56 2009 1965–2005 37 21 16 Hazard ratio, 2.8 (95% CI, 1.02–7.67)a II-3
Park et al57 2011 1989–2010 56 31 25 Odds ratio, 3.11 (95% CI,1.07–9.06)b II-3
George et al58 2014 2007–2012 58 39 19 Hazard ratio, 3.18 (95% CI,1.5–6.8)c II-3

CI, confidence interval.

a

Overall survival, multivariate adjusted model, P = .04;

b

Overall survival, multivariate adjusted model, P = .038;

c

Recurrence-free survival, multivariate adjusted model, P = .003.

Liu. Critical assessment of morcellation. Am J Obstet Gynecol 2015.